ISRCTN73459064
Active, Not Recruiting
N/A
Single centre drug-drug interaction study with levothyroxine and zinc-D-gluconate in healthy subjects
niversity Hospital of Zurich0 sites15 target enrollmentAugust 14, 2024
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hypothyroidism
- Sponsor
- niversity Hospital of Zurich
- Enrollment
- 15
- Status
- Active, Not Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age 18\-65 years old
- •2\. Informed Consent as documented by signature
Exclusion Criteria
- •1\. Contraindications to the drugs under study, e.g. known hypersensitivity or allergy
- •2\. Need for any kind of oral drug therapy (including oral contraceptive or nutritional supplements) for the duration of the study, except for the symptomatic treatment of common conditions like headache, musculoskeletal pain, common cold, gastritis, nausea and diarrhoea with medication containing paracetamol, non\-steroidal anti\-inflammatory drugs, meclizine, domperidone, and loperamide, as long they are taken on an as\-per\-need basis and not 72 hours before a visit.
- •3\. Planned intake of oral calcium, magnesium, zinc or iron supplements for the duration of the study
- •4\. Other clinically significant concomitant disease states (e.g., renal failure, thyroid dysfunction, cardiovascular disease, arterial hypertension, any other medical condition that could lead to an albumin deficiency such as anorexia etc.)
- •5\. Abnormal findings in the screening tests (laboratory, ECG, physical examination).
- •6\. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
- •7\. Participation in another study with an investigational drug within the 30 days preceding and during the present study
- •8\. Previous enrolment into the current study
- •9\. Enrolment of the investigator, his/her family members, employees and other dependent persons
- •Applicable only to female participants:
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 4
Drug interaction study with thyroid hormone and magnesium preparation in healthy volunteersHypothyroidismNutritional, Metabolic, EndocrineISRCTN18075783niversity Hospital of Zurich12
Completed
N/A
A One-Way Drug-Drug Interaction Study to Assess the Effect of Ritonavir-boosted Atazanavir on the Pharmacokinetics, Safety and Tolerability of BMS-790052 in Healthy SubjectsHepatitis Cviral liver inflammation10047438NL-OMON36726Bristol-Myers Squibb14
Completed
N/A
A ONE-WAY DRUG DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF BMS-790052 IN HEALTHY SUBJECTSHepatitis Cviral liver inflammation10047438NL-OMON36747Bristol-Myers Squibb17
Not Yet Recruiting
Phase 1
A Phase 1 Drug-Drug Interaction Study to Assess the Interaction Potential of NB-4746 on CYP1A2 and CYP3A4 Substrates in Healthy VolunteersACTRN12624001072505ura Bio18
Completed
Phase 1
Pharmacokinetic drug-drug interaction study between oral 300 mg netupitant/0.50 mg palonosetron fixed dose combination (Akynzeo®) and oral dexamethasone to evaluate the duration of the CYP3A4 inhibition in healthy subjectsInhibitory effect on CYP3A4Not ApplicableISRCTN93845260Helsinn Healthcare SA24